Infliximab biosimilar (Shanghai Biomabs)

英夫利西单抗生物类似药（上海百迈博制药）

Report date: 2025/12/10 17:16:55

Base Information

Drug NameInfliximab biosimilar (Shanghai Biomabs)
Drug Alias Name英夫利西单抗生物仿制药（上海百迈博制药）重组抗肿瘤坏死因子α人鼠嵌合单克隆抗体（上海百迈博制药）百类停类停CMAB-008 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[6] 
Global Approved IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[6] 
Approved Indications in ChinaPsoriasisCrohn DiseaseColitis, Ulcerative +[6] 
Original Approved Country/TerritoryMainland China
Original Approved Date2021/07/12
Country/TerritoryBangladeshPeruIndonesia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Biomabs Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Mabtech Pharmaceutical Co LtdMabpharm LtdShandong Kexing Bio-Products Co Ltd
Inactive CompaniesShanghai Biomabs Pharmaceuticals Co LtdShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksN/A